New-onset IgG autoantibodies in hospitalized patients with COVID-19

Sarah Esther Chang, Allan Feng, Wenzhao Meng, Sokratis A. Apostolidis, Elisabeth Mack, Maja Artandi, Linda Barman, Kate Bennett, Saborni Chakraborty, Iris Chang, Peggie Cheung, Sharon Chinthrajah, Shaurya Dhingra, Evan Do, Amanda Finck, Andrew Gaano, Reinhard Geßner, Heather M. Giannini, Joyce Gonzalez, Sarah Greib, Margrit Gündisch, Alex Ren Hsu, Alex Kuo, Monali Manohar, Rong Mao, Indira Neeli, Andreas Neubauer, Oluwatosin Oniyide, Abigail E. Powell, Rajan Puri, Harald Renz, Jeffrey Schapiro, Payton A. Weidenbacher, Richard Wittman, Neera Ahuja, Ho-Ryun Chung, Prasanna Jagannathan, Judith A. James, Peter S. Kim, Nuala J. Meyer, Kari C. Nadeau, Marko Radic, William H. Robinson, Upinder Singh, Taia T. Wang, E. John Wherry, Chrysanthi Skevaki (), Eline T. Luning Prak () and Paul J. Utz ()
Additional contact information
Sarah Esther Chang: Stanford University School of Medicine
Allan Feng: Stanford University School of Medicine
Wenzhao Meng: University of Pennsylvania
Sokratis A. Apostolidis: University of Pennsylvania
Elisabeth Mack: Philipps University Marburg
Maja Artandi: Stanford University School of Medicine
Linda Barman: Stanford University School of Medicine
Kate Bennett: University of Pennsylvania
Saborni Chakraborty: Stanford University School of Medicine
Iris Chang: Stanford University School of Medicine
Peggie Cheung: Stanford University School of Medicine
Sharon Chinthrajah: Stanford University School of Medicine
Shaurya Dhingra: Stanford University School of Medicine
Evan Do: Stanford University School of Medicine
Amanda Finck: University of Pennsylvania
Andrew Gaano: University of Pennsylvania
Reinhard Geßner: Philipps University Marburg
Heather M. Giannini: The University of Tennessee Health Science Center
Joyce Gonzalez: University of Pennsylvania
Sarah Greib: Philipps University Marburg
Margrit Gündisch: Philipps University Marburg
Alex Ren Hsu: Stanford University School of Medicine
Alex Kuo: Stanford University School of Medicine
Monali Manohar: Stanford University School of Medicine
Rong Mao: Stanford University School of Medicine
Indira Neeli: The University of Tennessee Health Science Center
Andreas Neubauer: Philipps University Marburg
Oluwatosin Oniyide: University of Pennsylvania
Abigail E. Powell: Stanford University School of Medicine
Rajan Puri: Stanford University School of Medicine
Harald Renz: Philipps University Marburg
Jeffrey Schapiro: Kaiser Permanente Northern California
Payton A. Weidenbacher: Stanford University School of Medicine
Richard Wittman: Stanford University School of Medicine
Neera Ahuja: Stanford University School of Medicine
Ho-Ryun Chung: Philipps University Marburg
Prasanna Jagannathan: Stanford University School of Medicine
Judith A. James: Oklahoma Medical Research Foundation
Peter S. Kim: The University of Tennessee Health Science Center
Nuala J. Meyer: University of Pennsylvania
Kari C. Nadeau: Stanford University School of Medicine
Marko Radic: The University of Tennessee Health Science Center
William H. Robinson: Stanford University School of Medicine
Upinder Singh: Stanford University School of Medicine
Taia T. Wang: Stanford University School of Medicine
E. John Wherry: University of Pennsylvania
Chrysanthi Skevaki: Philipps University Marburg
Eline T. Luning Prak: University of Pennsylvania
Paul J. Utz: Stanford University School of Medicine

Nature Communications, 2021, vol. 12, issue 1, 1-15

Abstract: Abstract COVID-19 is associated with a wide range of clinical manifestations, including autoimmune features and autoantibody production. Here we develop three protein arrays to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients. Autoantibodies are identified in approximately 50% of patients but in less than 15% of healthy controls. When present, autoantibodies largely target autoantigens associated with rare disorders such as myositis, systemic sclerosis and overlap syndromes. A subset of autoantibodies targeting traditional autoantigens or cytokines develop de novo following SARS-CoV-2 infection. Autoantibodies track with longitudinal development of IgG antibodies recognizing SARS-CoV-2 structural proteins and a subset of non-structural proteins, but not proteins from influenza, seasonal coronaviruses or other pathogenic viruses. We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (7)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-25509-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-25509-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-25509-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().